Incyte Corp. has identified Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of inflammatory disorders.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Nanjing Tian Yin Jian Hua Pharma Tech Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, multiple sclerosis, psoriasis, rheumatoid arthritis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), gout, inflammatory bowel and Alzheimer’s disease, among others.

Chengdu Chipscreen Pharmaceutical Ltd. has described ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Retune Pharma Inc. has divulged plasma kallikrein (KLKB1) inhibitors reported to be useful for the treatment of hereditary angioedema.

Scientists from Jordan Ministry of Higher Education Scientific Research and the Hashemite University have identified doxorubicin and thymoquinone hybridized compounds with reduced side effects reported to be useful for the treatment of breast cancer.

Lario Therapeutics Ltd. has synthesized voltage-dependent R-type calcium channel subunit α-1E (Cav2.3) blockers reported to be useful for the treatment of epilepsy, neurodegeneration, neurodevelopmental disorders, Parkinson’s disease, cerebral vasospasm and endocrine disorders.

Hainan Simcere Pharmaceutical Co. Ltd. has disclosed kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer.

Rpxds Co. Ltd. has described α-ketoglutarate-dependent dioxygenase FTO inhibitors reported to be useful for the treatment of obesity, diabetes, atherosclerosis and more.

Sporos Biodiscovery Inc. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.